Everything below concerns dihexa. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-28. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
=== Earliest appearances of features === Hadrocodium, whose fossils date from approximately 195 million years ago, in the early Jurassic, provides the first clear evidence of a jaw joint formed solely by the squamosal and dentary bones; there is no space in the jaw for the articular, a bone involved in the jaws of all early synapsids.
In histology, osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue. Osteoblasts begin the process of forming bone tissue by secreting the osteoid as several specific proteins. The osteoid and its adjacent bone cells have developed into new bone tissue when it becomes mineralized. Osteoid makes up about fifty percent of bone volume and forty percent of bone weight. It is composed of fibers and ground substance. The predominant type of fiber is type I collagen and comprises ninety percent of the osteoid. The ground substance is mostly made up of chondroitin sulfate and osteocalcin. Osteoblasts synthesize and secrete osteoid as an unmineralized organic matrix, and when the osteoid becomes mineralized through deposition of calcium salts, it transforms into mature bone tissue.
Benzodiazepines share a similar chemical structure, and their effects in humans are mainly produced by the allosteric modification of a specific kind of neurotransmitter receptor, the GABAA receptor, which increases the overall conductance of these inhibitory channels; this results in the various therapeutic effects as well as adverse effects of benzodiazepines. Other less important modes of action are also known. The term benzodiazepine is the chemical name for the heterocyclic ring system (see figure to the right), which is a fusion between the benzene and diazepine ring systems. Under Hantzsch–Widman nomenclature, a diazepine is a heterocycle with two nitrogen atoms, five carbon atom and the maximum possible number of cumulative double bonds. The "benzo" prefix indicates the benzene ring fused onto the diazepine ring. Benzodiazepine drugs are substituted 1,4-benzodiazepines, although the chemical term can refer to many other compounds that do not have useful pharmacological properties. Different benzodiazepine drugs have different side groups attached to this central structure. The different side groups affect the binding of the molecule to the GABAA receptor and so modulate the pharmacological properties. Many of the pharmacologically active "classical" benzodiazepine drugs contain the 5-phenyl-1H-benzo[e][1,4]diazepin-2(3H)-one substructure (see figure to the right). Benzodiazepines have been found to mimic protein reverse turns structurally, which enables them to exert their biological activity in many cases.
== Location == Using radioimmunoassay and immunocytochemistry, endomorphins have been localized within the nervous systems of humans, mice, rats, and monkeys. Both endomorphin tetrapeptides are abundant in the human neocortex. Endomorphin-1 can be found in the hypothalamus and thalamus of the diencephalon, and in the striatum and lateral septum of the telencephalon. In the hindbrain, endomorphin-1-reactive neurons are more abundant than are those immunoreactive for endomorphin-2. Endomorphin-2 is predominantly found in the spinal cord, specifically in presynaptic terminals of afferent neurons in the dorsal horn region. It has been found co-localized with calcitonin and with the pain-conveying neurotransmitter, substance P. Neither endomorphin-1 nor endomorphin-2 has been identified in the amygdala or the hippocampus.
== Career and Discoveries == In 2000, Sen joined The Ohio State University, where he was promoted to full professor with tenure in 2004 and later awarded the John H. & Mildred C. Lumley Endowed Chair of Surgery. At Ohio State, he also served as Associate Dean of Research. Sen was the founding Executive Director of the OSU Comprehensive Wound Center and the founding Director of the OSU Center for Regenerative Medicine & Cell-Based Therapies. His research at Ohio State focused on tissue injury, repair, regeneration, and infection, including studies on stroke, tissue reprogramming, and cutaneous wound healing. This work led to the development of Tissue Nanotransfection (TNT) technology for in vivo tissue reprogramming, published in Nature Nanotechnology. TNT received a 2018 Edison Awards for Innovation. Sen's work also advanced electroceutical approaches for managing tissue infection, earning the Frost & Sullivan Award for New Product Innovation. In 2021, he was elected a Lifetime Fellow of the National Academy of Inventors. In 2018, the Indianapolis Business Journal described Sen as “one of the world's leading experts in the nascent field of regenerative medicine” when he joined Indiana University as Director of the Indiana Center for Regenerative Medicine and Engineering (ICRME), Executive Director of IU Health Comprehensive Wound Center, J. Stanley Battersby Chair and Professor of Surgery, Associate Vice President of Research, and Associate Dean for Entrepreneurial Research. He brought a team of 30 researchers and $10 million in research funding.
Sources: en.wikipedia.org
Barry Finnerty – electric guitar Dewayne Pate – electric bass Barry Sless – pedal steel guitar Alex Maldonado – Native American flute Celso Alberti – drums, percussion Kevin Hayes – drums Gary Vogensen – electric guitar Dick Bright – violin
Thrombocytopenia, i.e. can be associated with heparin-induced thrombocytopenia (0.5-5.0% of persons treated for at least five days) Elevations in serum aminotransferases: 5.9%-6.1% In people undergoing abdominal or colorectal surgery: Bleeding, anemia, ecchymosis: ≥ 2% In persons undergoing hip or knee replacement: Fever, nausea, anemia, edema, peripheral edema: ≥ 2% In persons with severely restricted mobility during acute illness: Dyspnea, thrombocytopenia, confusion, diarrhea, nausea: ≥ 2% In people being treated for deep vein thrombosis: Injection site hemorrhage, injection site pain, hematuria: ≥ 2% Frequency under investigation
=== Ammunition === Most military use of depleted uranium has been as 30 mm ordnance, primarily the 30 mm PGU-14/B armor-piercing incendiary round from the GAU-8 Avenger cannon of the A-10 Thunderbolt II used by the United States Air Force. 25 mm DU rounds have been used in the M242 gun mounted on the U.S. Army's Bradley Fighting Vehicle and the Marine Corps's LAV-25. The U.S. Marine Corps uses DU in the 25 mm PGU-20 round fired by the GAU-12 Equalizer cannon of the AV-8B Harrier, and in the 20 mm M197 gun mounted on AH-1 Cobra helicopter gunships. The United States Navy's Phalanx CIWS's M61 Vulcan Gatling gun used 20 mm armor-piercing penetrator rounds with discarding plastic sabots and a core made using depleted uranium, however they later changed to using tungsten penetrators.
Linagliptin, sold under the brand name Tradjenta among others, is a medication used to treat type 2 diabetes (but not type 1) in conjunction with exercise and diet. Linagliptin is a dipeptidyl peptidase-4 inhibitor that works by increasing the production of insulin and decreasing the production of glucagon by the pancreas. It is generally less preferred than metformin and sulfonylureas as an initial treatment. It is taken by mouth. Common side effects include inflammation of the nose and throat. Serious side effects may include angioedema, pancreatitis, joint pain. Use in pregnancy and breastfeeding is not recommended. Linagliptin was approved for medical use in the United States, Japan, the European Union, Canada, and Australia in 2011. In 2023, it was the 254th most commonly prescribed medication in the United States, with more than 1 million prescriptions. From August 2021, linagliptin became available as a generic medicine in the US.
Sources: en.wikipedia.org
== Structure == The NDUFB2 gene, located on the q arm of chromosome 7 in position 34, is 9,966 base pairs long and is composed of 4 exons. The NDUFB2 protein weighs 12 kDa and is composed of 105 amino acids. NDUFB2 is a subunit of the enzyme NADH dehydrogenase (ubiquinone), the largest of the respiratory complexes. The structure is L-shaped with a long, hydrophobic transmembrane domain and a hydrophilic domain for the peripheral arm that includes all the known redox centers and the NADH binding site. NDUFB3 is one of about 31 hydrophobic subunits that form the transmembrane region of Complex I. It has been noted that the N-terminal hydrophobic domain has the potential to be folded into an alpha helix spanning the inner mitochondrial membrane with a C-terminal hydrophilic domain interacting with globular subunits of Complex I. The highly conserved two-domain structure suggests that this feature is critical for the protein function and that the hydrophobic domain acts as an anchor for the NADH dehydrogenase (ubiquinone) complex at the inner mitochondrial membrane. Hydropathy analysis revealed that this subunit and 4 other subunits have an overall hydrophilic pattern, even though they are found within the hydrophobic protein (HP) fraction of complex I.
Louis Circuit Attorney Kimberly Gardner. In February 2023, Circuit Judge David Mason found "clear and convincing evidence" that Johnson was not guilty and ordered his release in February 2023 after 28 years in prison. Schmitt also opposed the release Kevin Strickland, who served 43 years before his release in November 2021, on procedural grounds after Jean Peters-Baker, the prosecutor responsible for reviewing his case, publicly expressed her belief in his innocence. Schmitt's office took the position that the law allowing Peters-Baker to challenge the wrongful conviction required an adversarial process, in which the office of the Attorney General represented the state, as a check on local prosecutorial authority. A judge rejected a motion to retitle the case State of Missouri v. Jean Peters Baker. Despite their procedural argument, assistant attorney general Andrew Clarke said the office believed Strickland to be guilty and that he should remain incarcerated. In August 2021, Schmitt's office issued a subpoena requiring Peters-Baker to turn over any communication with third parties regarding the case, which she characterized as "harassment." After Strickland's release, Peters-Baker said Schmitt's handling of the case amounted to "prosecutorial malpractice" and referred to his procedural position as "profoundly idiotic".
=== Temporal lobe epilepsy === Epilepsy of the mesial temporal lobe is associated with HHV-6 infection. Within this region of the brain exists three structures: the amygdala, hippocampus, and parahippocampal gyrus. Mesial temporal lobe epilepsy (MTLE) is the most common form of chronic epilepsy and its underlying mechanism is not fully understood. Researchers consistently report having found HHV-6 DNA in tissues that were removed from patients with MTLE. Studies have demonstrated a tendency for HHV-6 to aggregate in the temporal lobe, with the highest concentrations in astrocytes of the hippocampus. However, one group of researchers ultimately concluded that HHV-6 may not be involved in MTLE related to mesial temporal sclerosis.
dysplasia The abnormal growth or development of a tissue or organ; a change in the growth, behavior, or organization of cells within a tissue, or the presence of cells of an abnormal type, such that the tissue becomes disordered, an event which often precedes the development of cancer.
== Comparisons to vertebrates == This open system might appear to be inefficient compared to the closed circulatory systems of the vertebrates, but the two systems have very different demands placed on them. In vertebrates, the circulatory system is responsible for transporting oxygen to all the tissues and removing carbon dioxide from them. It is this requirement that establishes the level of performance demanded of the system. The efficiency of the vertebrate system is far greater than is needed for transporting nutrients, hormones, and so on; whereas in insects, exchange of oxygen and carbon dioxide occurs in the tracheal system. Hemolymph plays no part in the process in most insects. Only in a few insects living in low-oxygen environments are there hemoglobin-like molecules that bind oxygen and transport it to the tissues. Therefore, the demands placed upon the system are much lower. Some arthropods and most molluscs possess the copper-containing hemocyanin, however, for oxygen transport.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.